Wells Fargo Reiterates Outperform On CRISPR Therapeutics, Raises Price Target To $95

Wells Fargo reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and raises the price target from $65 to $95.

Benzinga · 11/20/2019 15:00

Wells Fargo reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and raises the price target from $65 to $95.